Health
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J., January 12, 2026--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/3f9d436547b36730ef06a15c935edf48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iF3jeiUGyRuXwVzPlw7aZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3f9d436547b36730ef06a15c935edf48","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SxLMUYOQqq96DKQdzVYtHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3f9d436547b36730ef06a15c935edf48","width":1200,"height":165}},"lazy":false},{"type":"text","content":"SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpoints","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"The overall safety results in this study were consistent with the established safety profile of Camzyos in adults","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., January 12, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial met its primary endpoint, demonstrating a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 versus placebo, indicating Camzyos was effective in improving LVOT obstruction. Statistical significance was also met for multiple secondary endpoints, including those for clinically meaningful aspects of the disease. Safety results in the trial were consistent with the established safety profile of Camzyos in adults, and no new safety signals were reported in this new, younger population. The study continues with active treatment and long-term extension periods.","length":996,"tagName":"p"},{"type":"text","content":""Adolescent oHC...